Crescita Therpeutc (TSE:CTX) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Crescita Therapeutics Inc. experienced a challenging fiscal year in 2023, with a significant 26% drop in annual revenue largely due to decreased production for a major client. Despite this downturn, the skincare segment of the business grew by 30%, surpassing the beauty industry’s growth projections. The company remains optimistic about future prospects, including potential licensing deals and a strong cash position to fund strategic investments.
For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.